What happened
Shares of Exact Sciences (NASDAQ:EXAS), a molecular diagnostics company focused on the development of diagnostic tools to detect and prevent cancer, lost 16% of their value in October, according to data from S&P Global Market Intelligence. The reason for the drop can be traced to the company’s third-quarter earnings results, which were released on Oct. 26.
So what
For the quarter, Exact Sciences wound up generating $28.1 million from its Cologuard colorectal cancer diagnostic test.
